Positive 12-Month Follow-Up Data from Ph 2b CLOVER WaM Study Shows Durable Responses & Efficacy of Iopofosine I 131 in R/R Waldenström Macroglobulinemia May 12, 2026
Evorpacept + Zanidatamab combo Generates Durable Response in Patients with Advanced HER2+ve Breast Cancer and High CD47 Expression May 12, 2026
Interim Results Announced of US Alpha DaRT® REGAIN Trial, with 100% Local Disease Control, 67% CRR, and Favorable Safety Profile May 12, 2026
Updated Interim Results Announced From LEGEND Cohort of detalimogene voraplasmid in high-risk, BCG-unresponsive NMIBC patients with CIS with or without concomitant papillary disease May 12, 2026
50% ORR Announced in Recurrent Ovarian Cancer Ph 2 Trial of Ampligen, Pembrolizumab and Cisplatin May 12, 2026
Updated Positive Survival Observations from Ph 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy Reported May 12, 2026
Interim Ph 2 Data for INBRX-106 in 1L HNSCC Demonstrates Potential Costimulatory Benefit Over PD-1 Monotherapy May 12, 2026
Tovecimig Demonstrates Statistically Significant PFS Benefit but misses the OS benefit in COMPANION-002 Ph 2/3 Study in Patients with Biliary Tract Cancer May 6, 2026
Ph 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful PFS Improvement in PIK3CA Mutant Cohort May 6, 2026
Journal of Clinical Oncology Publishes Final Results of Duvelisib PRIMO Ph 2 Trial in R/R Peripheral T-cell Lymphoma May 6, 2026
Positive Ph 2a Data with Namodenoson in Pancreatic Cancer Reported; 35% of Patients Remain on Therapy, Including One Beyond 16 Months May 6, 2026
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Ph 2/3 Study in Patients with Biliary Tract Cancer April 28, 2026
Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination in 1L Metastatic Breast Cancer Announced April 28, 2026
LP-300 Demonstrates 8.3-Month Median PFS in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity April 28, 2026
FAILED TRIAL: Phase 3 LITESPARK-012 Trial of KEYTRUDA, LENVIMA, and WELIREG did not meet the dual primary endpoints of PFS and OS in 1L RCC April 28, 2026
Updated interim data from Ph 1/2 study of ozekibart (INBRX-109) + FOLFIRI in patients with metastatic CRC announced April 28, 2026
Darlifarnib + Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell RCC Previously Treated With Cabozantinib April 21, 2026
Daraxonrasib Demonstrates Unprecedented OS Benefit in Ph 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer April 21, 2026
Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer Presented April 21, 2026
Ph 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) Presented April 21, 2026
Results Announced from Ph 2 SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in ovarian cancer cohort and the cervical cancer cohorts April 21, 2026
